Objective: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. Cyclooxygenase-2 (COX-2) overexpression is associated with increased tumor invasiveness and proliferation in CRC, and COX-2 inhibition has demonstrated chemopreventive activity. This study investigated the addition of celecoxib, a selective COX-2 inhibitor, to the irinotecan, 5-fluorouracil, and leucovorin (IFL) regimen for patients with previously untreated metastatic CRC.
C olorectal cancer (CRC) is the third most common cancer in the United States, with ∼135,430 cases and 50,260 deaths projected in 2017. 1 Among patients with metastatic disease, the advancement in systemic treatment options has improved their expected median survival from 11 to 12 months with fluoropyrimidines alone in the 1990s to ∼2.5 years with modern combination therapies. 2, 3 Progress in the treatment of metastatic colorectal cancer (mCRC) over the past 2 decades has been steady. However, even negative randomized clinical trials have been informative and have opened new avenues for investigation using different approaches with biologically active agents.
Before the widespread adoption of FOLFOX and FOL-FIRI regimens in the United States, the irinotecan, 5-fluorouracil, and leucovorin (IFL) regimen, which incorporated bolus 5-fluorouracil (5-FU) infusion along with leucovorin (LV) and irinotecan, was a standard regimen with expected overall survival (OS) of 14.8 versus 12.6 months (P = 0.04), progressionfree survival (PFS) of 7.0 versus 4.3 months (P = 0.004), and response rate (RR) of 39% versus 21% (P < 0.001), when compared with irinotecan alone. 4 As subsequent randomized clinical trials optimized the combination chemotherapy backbone, incorporation of newer biological agents targeting specific pathways (such as antiangiogenic and antiepidermal growth factor receptor targets) moved forward quickly to demonstrate improved efficacy. 5 The cyclooxygenase-2 (COX-2) enzyme is overexpressed in the majority of CRCs and promotes tumor growth, invasiveness, and metastasis. 6 Several nonsteroidal anti-inflammatory drugs (NSAIDs), that inhibit COX-2 function to varying degrees, have demonstrated chemopreventive activity in CRC and adenoma development. [7] [8] [9] To begin exploring COX-2 inhibition in combination with chemotherapy as a therapeutic strategy, a phase I trial of celecoxib, at doses up to 200 mg orally twice daily, in combination with 5-FU and LV for patients with mCRC did not increase toxicities expected from chemotherapy. 10 Moreover, 5-FU/LV did not affect COX-2 inhibition by celecoxib. 10 Based upon the strong preclinical findings that COX-2 inhibition demonstrated antitumor activity, [11] [12] [13] [14] the clinical activity observed in chemoprevention trials, 7, 8 and the demonstrated safety in combining celecoxib with chemotherapy in mCRC, 10 we designed a single-arm proof-of-concept phase II study evaluating the addition of celecoxib to IFL, the standard first-line chemotherapy in the United States at the time of the study implementation, for patients with previously untreated mCRC.
PATIENTS AND METHODS

Study Design and Entry Criteria
From September 2000 to May 2003, patients with previously untreated unresectable or mCRC confirmed by biopsy were enrolled into this multicenter trial. The protocol was approved by each local institutional review board and was conducted in accordance with the Declaration of Helsinki. Patients were ineligible if they were candidates for further definitive resection or radiation. Prior adjuvant therapy with 5-FU (with or without LV or levamisole) for previously resected disease was permitted, provided that the recurrence occurred > 12 months from the end of adjuvant therapy, and patients had not experienced grade 3 or 4 toxicity from adjuvant chemotherapy.
Other eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 (ECOG performance status 2 was excluded after protocol amendment), age 18 years or older, life expectancy of at least 12 weeks, ability to give informed consent, and measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (version 1.0). Patients were required to have adequate hematologic, renal, and hepatic function (white blood cell count ≥ 3000/mm 3 , granulocytes ≥ 1500/mm 3 , platelets ≥ 100,000/ mm 3 , hemoglobin ≥ 8.0 g, bilirubin ≤ 2.0 mg/dL, SGOT ≤ 3 times upper limit of normal, albumin ≥ 3.0 g/dL, and creatinine clearance ≥ 50 mL/min). At least 4 weeks must have elapsed from any major surgery.
Patients were excluded from study entry if they required daily full-dose NSAIDs, including aspirin > 81 mg daily, for any reason. Patients taking cardiac-preventive doses of aspirin, defined as ≤ 81 mg daily, were eligible. All previous full-dose NSAIDs were discontinued 14 days before first dose of celecoxib. Additional exclusion criteria were the following: significant cardiovascular or cerebrovascular disease, venous thromboembolism, interstitial lung disease, symptomatic pleural effusion or ascites, bleeding disorder, bowel obstruction, chronic malabsorption, extensive bowel resections, active peptic ulcer disease, brain metastases or leptomeningeal disease, active second malignancy, pregnancy or lactation, uncontrolled infections, other significant medical or psychiatric disorders, known allergy or contraindication to NSAIDs or sulfonamides, chronic steroid use, or concomitant investigational medications.
Because of emerging cardiotoxicity concerns found in other trials using celecoxib during the time of study conduct, 15, 16 an independent data safety and monitoring committee paused the study after 22 patients were accrued in order to perform an unplanned interim analysis for toxicity evaluation. After no additional toxicity events were found, the study continued with the protocol amended to exclude patients with ECOG performance status 2 and to require low-dose aspirin ( ≤ 81 mg) for patients with specific cardiovascular risk factors defined as age ≥ 65 years, hypertension with systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 95, hypercholesterolemia with total blood cholesterol ≥ 240 mg/dL, smoking history, strong family history with a primary relative with myocardial infarction under age 55, or personal history of myocardial infarction, unstable angina, stroke, transient ischemic attack, peripheral vascular disease.
Therapy
Celecoxib was administered at 400 mg orally twice daily starting 2 weeks before chemotherapy (days 1 to 14). After the protocol amendment, patients with significant cardiovascular risk factors, were given aspirin 81 mg orally once daily starting with the first dose of celecoxib. IFL regimen was administered intravenously once weekly for 4 weeks on days 15, 22, 29, and 36 of each treatment cycle after initial 2 weeks of celecoxib runin. Celecoxib was given continuously throughout all 6 weeks. IFL consisted of irinotecan at a dose of 125 mg/m 2 , 5-FU at a dose of 500 mg/m 2 , and LV at a dose of 20 mg/m 2 . Treatment was continued until documentation of disease progression or until toxicities prohibited ongoing treatment, with a maximum of 24 months allowed on study drug.
Assessments
Tumor response by Response Evaluation Criteria in Solid Tumors criteria was assessed every 6 weeks for the first 3 cycles then every 3 months, or every other cycle, for subsequent cycles. Confirmation of complete or partial response was performed by repeat assessment at least 4 weeks after response criteria was first met, and confirmation of stable disease required repeat assessment at least 7 weeks after initial response criteria was met. Toxicity was assessed according to the NCI Common Toxicity Criteria (version 2.0).
Statistical Analysis
The primary endpoint was best objective RR (complete or partial response). Secondary endpoints included PFS, OS, and grade 3 or higher adverse events. PFS was defined as the time from the study entry to a documented disease progression or death, which ever occurred first. Patients who were alive and without progression at the end of the study period were censored on the date of the last known progression-free assessment. Kaplan-Meier method was used to estimate PFS and OS, and 95% exact binomial confidence interval was used to estimate median PFS and OS. Statistical analyses were performed separately using patients enrolled before and after the protocol modification in order to explore differences in outcomes due to protocol modification. Fisher exact test was used for categorical variables, and Wilcoxon rank sum test for continuous variables, and log rank test for survival outcomes. All analyses were performed using SAS version 9.0, and 2-sided P-values were reported.
The initial sample size estimate was based on a 2-sided, 1-sample binomial test with a 5% significance level, and power of 80%, to detect a 20% improvement in RR in comparison with historical controls (RR of 33% expected from IFL). 4, 17 Forty-eight evaluable subjects were required, and after allowing for a 10% dropout, a target sample size was set to 54 subjects. After protocol modification requiring aspirin 81 mg for highrisk subjects, the sample size was increased to a total of 78 subjects in order to allow the equivalent statistical power for meeting the primary endpoint. However, because of slow accrual, an unplanned interim analysis was performed which resulted in the study closure after it was found that the addition of celecoxib to IFL would not reach the target RR even with the increased sample size.
RESULTS
Patient Characteristics
A total of 49 patients met eligibility criteria, but 2 patients withdrew consent before receiving therapy. Of the 47 patients included in the analysis, 22 patients were enrolled on the original protocol, and 25 patients enrolled after the protocol amendment. Table 1 summarizes the baseline characteristics of all 47 patients. The mean age was 59.7 years, with a range of 21.4 to 80.1 years. Thirty-four (72.3%) patients were male, 29 (61.7%) were white, and 45 (95.7%) patients had ECOG score of 0 or 1. Patient characteristics appeared similar between those on the original protocol and those from after the protocol amendment except more patients were white in the original group (77.3% vs. 48%; P = 0.04), and there was a nonsignificant trend toward better ECOG status in the postprotocol population. The median duration of chemotherapy treatment was 3 cycles (range, 1 to 9 cycles) for all patients, 2.5 cycles (range, 1 to 9) before the amendment versus 4.0 cycles (range, 1 to 6) after the amendment (P = 0.08).
Efficacy
Data on best tumor response are summarized in Table 2 . Overall RR was 31.9%. One patient (2.1%) had a complete response as best overall response, whereas 14 patients (29.8%) had partial responses, 21 (44.7%) patients had stable disease, and 3 (6.4%) had progressive disease. No statistically significant difference was found in the RRs in patients accrued before or after the protocol amendment. Eight patients (17.0%) were not evaluable, but were included in the denominator for calculating RR.
Median PFS for all 47 patients was 8.7 months (95% confidence interval, 5.8-10.6), as detailed by Table 3 and Figures 1A and B . PFS did not significantly differ between those enrolled before and after protocol modification (median, 9.0 vs. 8.7 mo, respectively; P = 0.34). Six-month PFS was 68% (73% before modification and 67% after modification).
Median OS was 19.7 months, with median survival before protocol modification of 11.4 months, compared with 24.2 months after protocol modification (P < 0.0001), which is detailed by Table 3 and Figures 2A and B . One-year OS was 71%, with 46.7% before protocol modification, and 90.9% after protocol modification. Two patients in the preamendment portion of the study died during treatment: 1 from progressive disease, and 1 from toxicity.
Toxicity
Toxicity data were recorded for all 47 patients who received at least 1 dose of therapy. Table 4 lists the most common grade 3 or greater adverse events before and after protocol modification. Thirty-nine patients (83%) experienced at least 1 grade 3 or higher adverse event, most commonly neutropenia (31.9%), followed by diarrhea (21.3%), nausea/ vomiting (12.8%), and infection (8.5%). The incidence of most adverse events was similar before and after protocol modification except grade 3 or greater cardiovascular and thromboembolic events. As summarized in Table 5 , a total of 10 grade 3 or greater cardiac events occurred in 6 patients before the protocol amendment, including grade 5 cardiac arrest (1 patient), atrial fibrillation (2 patients), myocardial infarction (1 patient), congestive heart failure (1 patient), cerebrovascular accident (2 patients), hypotension (1 patient), hypertension (1 patient), and premature ventricular contractions (1 patient). The 1 patient with heart failure also had hypotension and a myocardial infarction, and the 1 patient who had grade 3 hypertension also had a cerebrovascular accident and premature ventricular contractions. All 6 patients had at least 1 cardiovascular risk factor at baseline but would not have been excluded under the amended protocol and were not mandated to take aspirin 81 mg until protocol modification. One of the 6 patients continued study treatment until disease progression. All significant cardiac adverse events occurred before protocol modification and none after (P = 0.02). Two occurrences of deep venous thrombosis occurred after protocol modification.
The most common reason for study discontinuation was progressive disease, both before protocol amendment in 11 (50%) patients, and after in 13 (52%) patients. Toxicity as the predominant reason for study discontinuation was evident in 4 (18%) patients before protocol amendment, and in 3 patients (12%) afterwards.
DISCUSSION
The addition of celecoxib to the IFL regimen (standard first-line chemotherapy in the United States at the time of the study implementation) for patients with previously untreated mCRC did not increase the tumor RR beyond that expected for IFL alone. 4, 17 This finding was based on an unplanned interim analysis where the primary endpoint of increased RR was unlikely to be achieved even if the target sample size were reached, which led to early termination of this trial. It should be noted that standard practice has adopted continuous 5-FU infusion regimens, such as FOLFOX or FOLFIRI, rather than the IFL regimen as the standard first-line chemotherapy backbone due to higher efficacy and less toxicity. 17, 18 In this study, PFS and OS seemed to be longer, 8.7 and 19.7 months, respectively, when compared with historical data at the time the study was carried out. However, this may reflect available subsequent lines of therapy as well as improved supportive care. Nevertheless, we cannot exclude the possibility of added survival benefit with celecoxib, as it is possible that it may slow progression rather than provide tumor response. In fact, both regorafenib and trifluridine/tipiracil, which are Food and Drug administration (FDA) approved for refractory mCRC, have RRs of <2%, yet there is a survival benefit. 19, 20 Thus, additional research exploring drug targets in the COX-2 pathway remains warranted.
Since the completion of this study, there have been other trials testing celecoxib in mCRC. A single-arm phase II study in France, OPTIMOX2 found that while celecoxib at 400 mg twice daily was safe to use with FOLFOX7, it did not increase the RR nor PFS when compared with historical results with FOLFOX. 21 Likewise, a randomized phase II study in Italy, GOIM 9901, which started patients on first-line FOLFIRI with either celecoxib or placebo, demonstrated that celecoxib was safe to use without any added gastrointestinal or cardiovascular toxicity from celecoxib with FOLFIRI, but it did not improve RRs nor time to progression. 22 The EORTC 40015 study, which used a 2-by-2 design comparing FOLFIRI to CAPIRI and celecoxib to placebo through a 1:1:1:1 randomization found increased toxicities, as 8 treatment-related deaths from gastrointestinal and thromboembolic events resulted in early trial closure. However, the high incidence of grade 3 or higher events were thought to be related to capecitabine in combination with irinotecan rather than from celecoxib. Moreover, there may have been a trend toward lower RRs in the celecoxib arms, though early termination of the study limits definitive conclusions. 23 Nevertheless, due to these results in mCRC trials [21] [22] [23] and other studies demonstrating increased cardiovascular risks with COX-2 inhibitors, 15, 16 ongoing trials at that time testing celecoxib in mCRC, such as the BICC-C study, closed the treatment arms containing celecoxib. 24 Multiple studies have examined the cardiovascular risks with celecoxib and concluded that there is a dose-related increase in cardiovascular events and deaths. 15, 16, 25 This study similarly observed a number of cardiovascular events until the protocol was modified to exclude patients with modest functional status and to mandate use of low-dose aspirin for those with risk factors for cardiovascular disease. The improvement in median survival from 11.4 months before protocol modification to 24.2 months after protocol modification likely reflects the advent of new treatment options after 2002, such as oxaliplatin and bevacizumab, rather than related to the protocol amendment. This suggestion is further supported by the lack of significant difference in PFS preamendment and postamendment. Cardiovascular risk is well recognized and regularly monitored when using other FDAapproved drugs for CRC, such as regorafenib and bevacizumab, and while it represents an unacceptable toxicity in chemoprevention trials, its use in incurable cancer is certainly still reasonable. Interestingly, aspirin has been observed to decrease CRC-specific mortality in patients with CRC, particularly if COX-2 expression were observed in the tumors. 9, 26 Thus, nonselective NSAIDs rather than COX-2 inhibitors, particularly aspirin, could serve as a safer alternative.
Study conclusions made from this trial were limited by the rapidly changing landscape in mCRC in the early 2000s, including the adoption of 5-FU continuous infusion over bolus, establishment of FOLFOX and FOLFIRI as the preferred chemotherapy backbone, FDA approval of bevacizumab and cetuximab, and recognition of cardiovascular risk from COX-2 inhibitors, which all contributed to slow accrual on this study. The single-arm design with a major protocol modification also made comparison to historical data difficult, and it also could have introduced an unintended selection bias enrolling healthier patients with fewer cardiovascular risk factors to participate in the trial postprotocol modification. Moreover, there was inadequate statistical power to examine the cardiovascular and gastrointestinal toxicity before and after protocol modification. In addition, current relevant prognostic factors such as mutational status of RAS and BRAF, microsatellite instability, and site of primary tumor (right vs. left), were not known and thus not collected at the time of this study. Hence, it remains possible that such imbalances prestudy and poststudy modification could have influenced our findings.
In conclusion, the addition of celecoxib to IFL did not improve RRs compared with what is expected from IFL alone. It may be that despite preclinical antitumor effects and chemopreventive activity for premalignant lesions, celecoxib has less impact upon larger disease burden and only more of a disease control (or cytostatic) effect. Celecoxib may also be more clinically relevant in a microscopic tumor disease state. Interestingly, there is an ongoing Alliance/SWOG 80702 study testing the benefit of celecoxib to adjuvant FOLFOX in stage III colon cancer, a disease state that at most has only microscopic disease rather than overt metastatic disease and these results are eagerly awaited (https://clinicaltrials.gov/show/NCT01150045). However, because our trial was unable to meet its primary endpoint in addition to safety concerns, it remains to be seen what the ultimate role, and in what clinical context, the modulation of the COX-2 pathway will play in the treatment of CRC. 
